Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.45 |
| ▸ | CSNK2B | P67870 | 2/20 | 0.45 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.45 |
| ▸ | KDR | P35968 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.42 |
| ▸ | HPGD | P15428 | 5/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | DAO | P14920 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.41 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14269800 | 0.83 | MAPT (0.37) | CSNK2A2CSNK2BCSNK2A1KDRKDM4E | |
| SCHEMBL1529974 | 0.82 | GSK3B (0.53) | CSNK2A2CSNK2BCSNK2A1KDRKDM4E | |
| SCHEMBL1472954 | 0.82 | DAO (0.63) | KDM4EHPGDALDH1A1MAPTDAO | |
| SCHEMBL6739730 | 0.81 | PTPN2 (0.46) | KDM4EHPGDALDH1A1MAPK1NPC1 | |
| SCHEMBL17201680 | 0.81 | PTPN2 (0.43) | CSNK2A2CSNK2BCSNK2A1KDRKDM4E | |
| SCHEMBL9925990 | 0.80 | KDM4E (0.67) | CSNK2A2CSNK2BCSNK2A1KDRKDM4E | |
| SCHEMBL29271619 | 0.79 | KDM4E (0.41) | CSNK2A2CSNK2BCSNK2A1KDRKDM4E | |
| SCHEMBL20892550 | 0.79 | MRGPRX4 (0.43) | CSNK2A2CSNK2BCSNK2A1KDRKDM4E | |
| SCHEMBL45690 | 0.78 | MAPT (0.42) | KDM4EALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL16302070 | 0.77 | DAO (0.69) | CSNK2A2CSNK2BCSNK2A1KDRKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 157 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023211855-A1 | KCNT1 INHIBITORS COMPRISING A THIOPHENE CORE AND METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2023-11-02 | — | — | WO | disclosed |
| EP-3466946-B1 | THIOPHENE, MANUFACTURING METHOD THEREOF, AND PHARMACEUTICAL APPLICATION OF SAME | DONGBAO PURPLE STAR HANGZHOU BIOPHARMACEUTICAL CO LTD (CN) | 2023-08-30 | — | — | EP | disclosed |
| CN-116462679-A | Pyrazolopyrimidine derivative and application thereof in medicine | 四川海思科制药有限公司 | 2023-07-21 | — | — | CN | disclosed |
| CN-109996790-B | Piperazine carbamates and methods of making and using the same | H.隆德贝克有限公司 | 2023-05-16 | — | — | CN | disclosed |
| EP-3515897-B1 | PIPERAZINE CARBAMATES AS MODULATORS OF MAGL AND/OR ABHD6 AND THEIR USE | H LUNDBECK AS (DK) | 2021-08-18 | — | — | EP | disclosed |
| US-10899737-B2 | Piperazine carbamates and methods of making and using same | LUNDBECK LA JOLLA RESEARCH CENTER, INC. (US) | 2021-01-26 | — | — | US | disclosed |
| US-10829483-B2 | Thiophene, manufacturing method thereof, and pharmaceutical application of same | CSTONE PHARMACEUTICAL (SUZHOU) CO., LTD. (CN) | 2020-11-10 | — | — | US | disclosed |
| US-20200140423-A1 | Thiophene, Manufacturing Method Thereof, And Pharmaceutical Application Of Same | DONGBAO PURPLE STAR (HANGZHOU) BIOPHARMACEUTICAL CO., LTD (CN) | 2020-05-07 | — | — | US | disclosed |
| EP-2496230-B1 | IRE-1 ALPHA INHIBITORS | FOSUN ORINOVE PHARMATECH INC (CN) | 2020-02-26 | — | — | EP | disclosed |
| EP-2496230-B1 | IRE-1 ALPHA INHIBITORS | FOSUN ORINOVE PHARMATECH INC (CN) | 2020-02-26 | — | — | EP | disclosed |
| WO-2005066180-A1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2005-07-21 | — | — | WO | disclosed |
| EP-0773943-B1 | COMPOUNDS USEFUL AS ANTIPROLIFERATIVE AGENTS AND GARFT INHIBITORS | AGOURON PHARMA (US) | 2001-09-26 | — | — | EP | disclosed |
| US-5840917-A | ADMINISTERING TO MAMMAL TO ERADICATE HELICOBACTER PYLORI | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-11-24 | — | — | US | disclosed |
| WO-1998042347-A1 | PHARMACEUTICAL COMPOSITION CONTAINING A PHOSPHORYLAMIDE AND AN AYNTIBIOTIC | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-10-01 | — | — | WO | disclosed |
| EP-0852498-A1 | PHOSPHORYLAMIDES, THEIR PREPARATION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1998-07-15 | — | — | EP | disclosed |
| US-5646141-A | THIENYLALKYLATED DERIVATIVES OF PYRIDO(2,3-D)-PYRIMIDINE, PYRIMIDO(5,4-6)-(1,4)THIAZINE OR PYRIMIDO(5,4-6)-(1,4)SELENAZINE | AGOURON PHARMACEUTICALS, INC. (US) | 1997-07-08 | — | — | US | disclosed |
| EP-0773943-A1 | COMPOUNDS USEFUL AS ANTIPROLIFERATIVE AGENTS AND GARFT INHIBITORS | AGOURON PHARMACEUTICALS, INC. (US) | 1997-05-21 | — | — | EP | disclosed |
| WO-1997011705-A1 | PHOSPHORYLAMIDES, THEIR PREPARATION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-04-03 | — | — | WO | disclosed |
| US-5608082-A | GARFT = THE ENZYME GLYCINAMIDE RIBONUCLEOTIDE FORMYL TRANSFERASE | AGOURON PHARMACEUTICALS, INC. (US) | 1997-03-04 | — | — | US | disclosed |
| WO-1996003406-A1 | COMPOUNDS USEFUL AS ANTIPROLIFERATIVE AGENTS AND GARFT INHIBITORS | AGOURON PHARMACEUTICALS, INC. (US) | 1996-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10899737-B2 | Piperazine carbamates and methods of making and using same | ABHD6, RABL6, ABHD16A | CSNK2A2 4110/4885CSNK2B 4552/4885CSNK2A1 4415/4885 |
| US-10829483-B2 | Thiophene, manufacturing method thereof, and pharmaceutical application of same | SLC10A6, TPMT, SLC6A6 | CSNK2A2 3150/4885CSNK2B 3558/4885CSNK2A1 3123/4885 |
| US-20200140423-A1 | Thiophene, Manufacturing Method Thereof, And Pharmaceutical Application Of Same | SLC10A6, TPMT, SLC6A6 | CSNK2A2 3150/4885CSNK2B 3558/4885CSNK2A1 3123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.